

Serial No.: 09/273,230

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1.-41. (cancelled)
42. (currently amended) A method for treating cancer characterized by overexpression of HER2 receptor in a mammal comprising administering to the mammal subcutaneously a therapeutically effective amount of a formulation comprising an antibody which binds HER2 receptor in an amount of about ~~80~~ 50 mg/mL to about 400mg/mL.
43. (cancelled)
44. (previously presented) The method of claim 42 wherein the formulation has been prepared by reconstituting lyophilized antibody in a diluent.
45. (previously presented) The method of claim 42 wherein the mammal is a human.
46. (previously presented) The method of claim 42 wherein the cancer is selected from the group consisting of breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon and bladder cancer.
47. (currently amended) A method for treating a human comprising administering subcutaneously a therapeutically effective amount of a stable reconstituted formulation to the human in order to treat cancer characterized by overexpression of HER2 receptor in the human, wherein the reconstituted formulation comprises an antibody which binds HER2 receptor in an amount of about ~~80~~ 50 mg/mL to about 400mg/mL and has been prepared by reconstituting a lyophilized mixture of the antibody and a lyoprotectant in a diluent, wherein the antibody concentration in the reconstituted formulation is about 2-40 times greater than the antibody concentration in the mixture before lyophilization.
- 48.-50. (cancelled)

Serial No.: 09/273,230

51. (new) The method of claim 42 wherein the cancer is breast cancer.
52. (new) The method of claim 47 wherein the cancer is breast cancer.